🏛️ Verified NIH Record • Updated 2026-07-23

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (NCT06494878)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: University of Calgary

🩺 Plain-English Summary (8th-Grade Level)

The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (12 items) and avoid the listed exclusions (15 items).

Location: Association Hospitalière De Bruxelles Et De Schaerbeek - Centre Hospitalier Universitaire Brugmann — Brussels

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • More than 48 hours since delivery at the time of randomization
  • Received more than 1 dose of LMWH since delivery
  • Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by their physician and/or local investigator. May include but is not limited to:
  • Documented history of provoked or unprovoked VTE
  • Mechanical heart valve(s)
  • Known antiphospholipid syndrome (APS)
  • Known high-risk inherited thrombophilia i) Antithrombin deficiency, or ii) Homozygous factor V Leiden, or iii) Homozygous prothrombin gene mutation, or iv) More than 1 thrombophilia: any combination of 2 or more: factor V Leiden, prothrombin gene mutation, protein C deficiency, protein S deficiency
  • Need for postpartum ASA as judged by their physician and/or local investigator. May include but is not limited to:
  • Documented history of myocardial infarction
  • Documented history of ischemic stroke or transient ischemic attack (TIA)
  • Active bleeding, excluding normal vaginal bleeding, at the time of randomization

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (12 Sites)

  • Association Hospitalière De Bruxelles Et De Schaerbeek - Centre Hospitalier Universitaire Brugmann — Brussels,
  • Foothills Medical Centre — Calgary, Alberta
  • The Ottawa Hospital - General Campus — Ottawa, Ontario
  • Hvidovre Hospital — Hvidovre, Capital Region
  • CHU de Nancy — Nancy,
  • APHP - Hôpital Port Royal — Paris,
  • CHU de Saint-Etienne — Saint-Etienne,
  • CHU de Toulouse — Toulouse,
  • Rotunda Hospital, RCSI Department of Obstetrics and Gynaecology — Dublin,
  • UCD Centre for Human Reproduction, The Coombe Hospital — Dublin,
  • Amsterdam UMC — Amsterdam,
  • Medical University of Warsaw — Warsaw,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗